Major Depressive Disorder (MDD) Clinical Trial
Official title:
A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs. Vilazodone HCl under the trade name Viibryd™ is approved by the U.S. FDA for the treatment of major depressive disorder in adults. The purpose of this study is to evaluate the efficacy (how well the drug works), safety (the side effects), and tolerability (how well tolerated) of Vilazodone in preventing relapse or recurrence of depression. As vilazodone is not approved by the United States Food and Drug Administration (FDA) to prevent the recurrence of depression, for the purposes of this study it is considered investigational. The word "investigational" means that the study drug is still being tested in research studies and has not been approved for this use by the FDA.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
| Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
| Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
| Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
| Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
| Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
| Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
| Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
| Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
| Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
| Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT04403373 -
Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study
|
N/A | |
| Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
| Recruiting |
NCT06385405 -
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
|
N/A | |
| Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
| Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
| Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
| Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
| Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 |